JPS6245201B2 - - Google Patents
Info
- Publication number
- JPS6245201B2 JPS6245201B2 JP59052496A JP5249684A JPS6245201B2 JP S6245201 B2 JPS6245201 B2 JP S6245201B2 JP 59052496 A JP59052496 A JP 59052496A JP 5249684 A JP5249684 A JP 5249684A JP S6245201 B2 JPS6245201 B2 JP S6245201B2
- Authority
- JP
- Japan
- Prior art keywords
- chloride
- group
- nicotinic acid
- skin
- carbamidopyridinium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 description 4
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 4
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 231100000344 non-irritating Toxicity 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- -1 phosphate ester Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010008528 Chillblains Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPUJEWVVTKLMQI-UHFFFAOYSA-N benzene;ethoxyethane Chemical compound CCOCC.C1=CC=CC=C1 WPUJEWVVTKLMQI-UHFFFAOYSA-N 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Description
この発明は、安全性が高く、界面活性機能もす
ぐれ、しかも皮膚に対する作用も温和なニコチン
酸誘導体を界面活性剤もしくは静菌剤またはこれ
ら両剤として利用することを目的とする皮膚外用
剤に関するものである。
ニコチン酸はナイアシンとも呼ばれるビタミン
B3で生体内において生命現象を維持する上で重
要な酸化還元酵素の補酵素ニコチンアミドアデニ
ンジヌクレオチド(NAD+)とそのリン酸エステ
ル(NADP+)を構成する。また、ペラグラ治療、
慢性アルコール中毒、しもやけ、舌炎の治療など
に有効であることもよく知られている。
一方、アルキルピリジニウム塩、アルキルトリ
メチルアンモニウム塩、アルキルジメチルベンジ
ルアンモニウム塩などはリンス剤、殺菌剤、柔軟
剤、帯電防止剤などの広い分野で汎用されている
陽イオン界面活性剤であるが、これらを皮膚に塗
布したままのときには、界面活性剤特有の副作用
である強い刺激性があり、主としてヘアコンデイ
シヨナー、トリートメントなどの化粧料以外に使
用するのは好ましくない。
この発明はこのような現状に着目してなされた
ものであり、下記一般式〔A〕または〔B〕で表
わされるニコチン酸誘導体を含有することを特徴
とする皮膚外用剤を提供するものである。
記
(式中、R1は炭素数8〜30の直鎖もしくは分枝ア
ルキル基、R2は炭素数1〜30の直鎖もしくは分
枝アルキル基およびフエニル基、Xはハロゲン基
を表わす。)
以下、この発明の詳細を述べる。
まず、この発明に適用される一般式〔A〕で示
される1−アルキル−3−カルバミドピリジニウ
ム塩および一般式〔B〕で示される1−アルキル
−3−アルキルカルバミドピリジニウム塩は、こ
の発明者らがニコチン酸アミドの生理的効果効能
に注目して検討した結果見出したもので、補酵素
NAD+モデル化合物であり、明らかに天然系界面
活性剤に分類されるものである。そして、このよ
うな化合物が界面領域に存在するときには、油性
成分をきわめて容易に乳化することができるが、
これはおそらくピリジニウム骨格と他の配合成分
との間に広義の電荷移動錯体が形成されるものと
考えられるが、形成されたミセルやエマルジヨン
はきわめて安定性がよく、界面活性機能および静
菌機能を有し、従来の陽イオン界面活性剤では得
られない低刺激性の化粧水、乳液、クリーム、ヘ
アコンデイシヨナー等の皮膚外用剤に適用できる
のである。
このようなニコチン酸誘導体を合成する方法は
数多くあるが、たとえば〔A〕に対してはニコチ
ン酸アミドにエタノール、ジメチルホルムアミド
等の溶媒下所望のアルキルハライドを反応させる
方法が有利であり、また、〔B〕に対してはニコ
チン酸に過剰の塩化チオニルなどの塩素化剤を作
用させニコチン酸クロライドとし、これにベンゼ
ン等の溶媒下、トリエチルアミン等の塩基存在
下、アルキルアミンを作用させて3−アルキルカ
ルバミドピリジンを生成せしめ、さらに、これに
エタノール等の溶媒下、所望のアルキルハライド
を反応させるという方法が有利である。これら方
法の具体例はつぎのとおりである。
〔A〕の合成例:
ニコチン酸アミド1.22g(0.01mol)をジメチ
ルホルムアミド15mlに溶解し、ステアリルクロラ
イド2.89g(0.01mol)を加え、還流下2時間反
応させ、ついで室温まで放冷した。生成した白色
結晶を吸引濾過し、エーテルで洗浄し、2.5gの
1−ステアリル−3−カルバミドピリジニウムク
ロライドを得た。一方濾液のジメチルホルムアミ
ド溶液を数mlになるまで濃縮し、一度加熱した
後、氷冷下にて一昼夜放置して、同一物1.2gを
得た。この合成例における全収率は90%であつ
た。
〔B〕の合成例:
ニコチン酸1.85g(0.015mol)に塩化チオニル
10mlを加え、70〜80℃にて1時間攪拌した。反応
後塩化チオニルを蒸留によつて除き、ニコチン酸
クロライドの結晶を密封して保存した。一方、ス
テアリルアミン2.70g(0.01mol)をベンゼン100
mlに溶解し、さらにトリエチルアミン10mlを加え
た混合液に前記のニコチン酸クロライドを室温下
に加え、後55〜60℃にて2時間攪拌した。反応後
40mlの水を加え、氷冷下静置し、生成した結晶を
濾別し、これをn−ヘキサン−ベンゼンにて再結
晶し、3−ステアリルカルバミドピリジン3.20g
を得た。得られた結晶1.88g(5mmol)に20ml
のエタノールを加え、ついでベンジルクロライド
2.52g(20mmol)をこれに加え、還流下5時間
反応させた。反応後エタノールを蒸留によつて除
き、生成した結晶を石油エーテル−ベンゼンを用
いて再結晶し、2.34gの1−ベンジル−3−ステ
アリルカルバミドピリジニウムクロライドが得ら
れた。
以上述べたこの発明の皮膚外用剤を通常の化粧
料に利用しようとするときには公知の配合成分を
随時加えればよく、また、必要に応じて、保湿
剤、増粘安定剤、防腐剤、着色剤、着香料等を添
加してもよい。このようにして作られた化粧料は
長期間保存しても広い温度領域で安定性を保ち、
皮膚に対する安全性はきわめて高くしかも優れた
作用効果を示して良好な使用感触を与えるもので
あるから、その商品価値は非常に高いものである
と言うことができる。
以下この発明の実施例を示す。なお、配合割合
(%)はすべて重量%である。
実施例 1
つぎに示す組成のクリームリンスを調製した。
第1群:
1−ステアリル−3−カルバミドピリジニウムク
ロライド 0.4%
セトステアリルアルコール 2.5
パラフインワツクス 1.0
パルミチン酸イソプロピル 0.5
オリーブ油 0.5
香 料 0.3
防腐剤 0.2
第2群:
色 素 適量
精製水 残り全部
すなわち、まず第1群の混合物を80℃に加熱溶
解し、これに、第2群の80℃溶液を加え、ホモミ
キサーで均質化処理をした後冷却した。得られた
クリームリンスは45℃のオーブンテストの結果に
おいて3カ月以上も安定であり、刺激性はなく、
使用感も非常に優れていた。なお、1−ステアリ
ル−3−カルバミドピリジニウムクロライドの代
わりに、塩素以外の臭素、フツ素、ヨウ素からな
るハライドを用いて全く同様の処理を行ないクリ
ームリンスを調製したが、いずれも同様の性状を
示した。
実施例 2
つぎに示す組成のクレンジングローシヨンを調
製した。調製手順は実施例1と全く同じである。
第1群:
1−セチル−3−カルバミドピリジニウムクロラ
イド 0.8%
セトステアリルアルコール 1.2
ワセリン 5.0
流動パラフイン 11.0
パルミチン酸イソプロピル 2.0
香 料 0.1
防腐剤 0.2
第2群:
1・3−ブチレングリコール 5.0
精製水 74.7
得られたクレンジングローシヨンは45℃のオー
ブンテストにおいても3カ月以上安定であり、刺
激性はなく、使用感は非常に良好であつた。
実施例 3
つぎに示す組成のスキンクリームを調製した。
第1群:
1−ステアリル−3−カルバミドピリジニウムク
ロライド 1.0%
セトステアリルアルコール 5.0
スクワラン 10.0
ステアリン酸 8.0
ミツロウ 2.0
オリーブ油 3.0
香 料 0.1
防腐剤 0.2
第2群:
1・3−ブチレングリコール 8.0
グリセリン 4.0
精製水 58.7
調製手順は実施例1と全く同じであり、得られ
たスキンクリームは45℃のオーブンテストにおい
ても3カ月以上も安定であり、刺激性がなく使用
感も非常に良好であつた。
実施例 4
つぎに示す組成のクレンジングクリームを調製
した。
第1群:
1−ベンジル−3−ステアリルカルバミドピリジ
ニウムクロライド 2.0%
セトステアリルアルコール 3.0
流動パラフイン 35.0
パラフインワツクス 2.0
パルミチン酸イソプロピル 10.0
第2群:
マルチトール 3.0
精製水 45.0
調製手順は実施例1と全く同じであり、得られ
たクレンジングクリームは45℃のオーブンテスト
において3カ月以上も安定であり、刺激性がなく
使用感も非常に良好であつた。
実施例 5
つぎに示す組成の化粧水を調製した。
第1群:
1−ラウリル−3−カルバミドピリジニウムクロ
ライド 0.60%
香 料 0.20
オレイルアルコール 0.04
1・3−ブチレングリコール 1.00
グリセリン 1.00
第2群:
クエン酸 0.07
精製水 97.06
すなわち、第1群からなる溶液に第2群の水溶
液を加え、均一透明に溶解するまで充分に攪拌し
た。得られた透明化粧水は、皮膚に対する作用も
温和であり、通常の化粧水に配合されるエチルア
ルコールを使用することなく、香料、オイル類を
可溶化するために、肌に対する使用感は非常に良
好であつた。
なお、実施例1〜5について、静菌効果を調べ
たところ、少なくとも雑菌については顕著なもの
が認められた。
実施例 6
人パツチテストをつぎの検査方法および判定方
法で実施した。
(1) 貼付材料 Finn chamber
(2) 貼付部位 上腕内側
(3) 貼付時間 24時間
(4) 判定 除去後1時間および7時間
(5) 判定基準 本邦基準
(−)無反応
(±)わずかな紅斑
(+)明らかな紅斑
(〓) 紅斑+浮腫または丘疹
(〓) 紅斑+浮腫+丘疹または小水疱
(〓) 紅斑+浮腫+丘疹+小水疱
(6) 試料
有効成分として角試料の0.5w/w%水溶液
を15ml使用した。
(a) 蒸留水(ブランク)
(b) 1−ステアリル−3−カルバミドピリジウ
ムクロライド(本発明品)
(c) セチルピリジニウムクロライド(対照品)
(d) 1−ドデシル−3−オキシピリジニウムブ
ロミド(対照品)
(e) セチルトリメチルアンモニウムクロライド
(対照品)
得られた結果を第1表に示した、この表から1
−ステアリル−3−カルバミドピリジニウムクロ
ライド(本発明品)の一次刺激性は蒸留水と同程
度であり、他の陽イオン界面活性剤(粧原基適合
品)よりきわめて低刺激性であると考えられる。
This invention relates to an external skin preparation that aims to utilize nicotinic acid derivatives, which are highly safe, have excellent surfactant functions, and have mild effects on the skin, as a surfactant, a bacteriostatic agent, or both. be. Nicotinic acid is a vitamin also known as niacin.
B3 constitutes the coenzyme nicotinamide adenine dinucleotide (NAD + ) and its phosphate ester (NADP + ), which are important oxidoreductase enzymes in maintaining life phenomena in living organisms. Also, pellagra treatment,
It is also well known to be effective in treating chronic alcoholism, chilblains, and glossitis. On the other hand, alkylpyridinium salts, alkyltrimethylammonium salts, alkyldimethylbenzylammonium salts, etc. are cationic surfactants that are widely used in a wide range of fields such as rinse agents, disinfectants, softeners, and antistatic agents. When left on the skin, it causes strong irritation, which is a side effect characteristic of surfactants, so it is not preferable to use it for anything other than cosmetics, such as hair conditioners and treatments. The present invention has been made in view of the current situation, and provides an external skin preparation characterized by containing a nicotinic acid derivative represented by the following general formula [A] or [B]. . Record (In the formula, R 1 represents a straight chain or branched alkyl group having 8 to 30 carbon atoms, R 2 represents a straight chain or branched alkyl group having 1 to 30 carbon atoms and a phenyl group, and X represents a halogen group.) , the details of this invention will be described. First, the 1-alkyl-3-carbamide pyridinium salt represented by the general formula [A] and the 1-alkyl-3-alkylcarbamide pyridinium salt represented by the general formula [B] that are applied to this invention are This was discovered as a result of a study focusing on the physiological effects and efficacy of nicotinamide.
It is a NAD + model compound and is clearly classified as a natural surfactant. When such compounds are present in the interfacial region, oily components can be emulsified very easily.
This is probably due to the formation of charge transfer complexes in a broad sense between the pyridinium skeleton and other formulation components, but the micelles and emulsions formed are extremely stable and have surfactant and bacteriostatic functions. It can be applied to external skin preparations such as lotions, emulsions, creams, and hair conditioners, which have hypoallergenic properties that cannot be obtained with conventional cationic surfactants. There are many methods for synthesizing such nicotinic acid derivatives, but for example, for [A], a method in which nicotinic acid amide is reacted with a desired alkyl halide in a solvent such as ethanol or dimethylformamide is advantageous; For [B], nicotinic acid is reacted with an excess chlorinating agent such as thionyl chloride to form nicotinic acid chloride, and this is reacted with an alkylamine in a solvent such as benzene in the presence of a base such as triethylamine to form 3- An advantageous method is to generate an alkylcarbamide pyridine and then react it with a desired alkyl halide in a solvent such as ethanol. Specific examples of these methods are as follows. Synthesis example of [A]: 1.22 g (0.01 mol) of nicotinamide was dissolved in 15 ml of dimethylformamide, 2.89 g (0.01 mol) of stearyl chloride was added, the mixture was reacted under reflux for 2 hours, and then allowed to cool to room temperature. The produced white crystals were filtered with suction and washed with ether to obtain 2.5 g of 1-stearyl-3-carbamidopyridinium chloride. On the other hand, the dimethylformamide solution of the filtrate was concentrated to several ml, heated once, and left overnight under ice cooling to obtain 1.2 g of the same product. The overall yield in this synthesis example was 90%. Synthesis example of [B]: 1.85 g (0.015 mol) of nicotinic acid and thionyl chloride
10 ml was added and stirred at 70-80°C for 1 hour. After the reaction, thionyl chloride was removed by distillation, and the nicotinic acid chloride crystals were sealed and stored. Meanwhile, 2.70 g (0.01 mol) of stearylamine was added to 100 g of benzene.
ml and further added 10 ml of triethylamine, the above nicotinic acid chloride was added at room temperature, and the mixture was stirred at 55 to 60°C for 2 hours. After reaction
Add 40 ml of water, leave to stand under ice cooling, filter the formed crystals, recrystallize from n-hexane-benzene, and obtain 3.20 g of 3-stearylcarbamide pyridine.
I got it. 20ml to 1.88g (5mmol) of the obtained crystals
of ethanol, then benzyl chloride
2.52 g (20 mmol) was added thereto and reacted under reflux for 5 hours. After the reaction, ethanol was removed by distillation, and the resulting crystals were recrystallized using petroleum ether-benzene to obtain 2.34 g of 1-benzyl-3-stearylcarbamide pyridinium chloride. When the skin external preparation of the present invention described above is to be used in ordinary cosmetics, known ingredients may be added as needed, and if necessary, moisturizers, thickening stabilizers, preservatives, and colorants may be added. , flavoring agents, etc. may be added. Cosmetics made in this way remain stable over a wide temperature range even after long-term storage.
It can be said that its commercial value is extremely high because it is extremely safe for the skin, exhibits excellent effects, and provides a good feel when used. Examples of this invention will be shown below. In addition, all compounding ratios (%) are weight %. Example 1 A cream rinse having the following composition was prepared. Group 1: 1-stearyl-3-carbamidopyridinium chloride 0.4% Cetostearyl alcohol 2.5 Parafine wax 1.0 Isopropyl palmitate 0.5 Olive oil 0.5 Fragrance 0.3 Preservative 0.2 Group 2: Pigment Appropriate amount of purified water All the rest In other words, first The mixture of the first group was heated and dissolved at 80°C, and the 80°C solution of the second group was added thereto, homogenized using a homomixer, and then cooled. The obtained cream rinse was stable for more than 3 months in an oven test at 45°C, and was non-irritating.
The usability was also very good. A cream rinse was prepared in exactly the same manner using a halide other than chlorine consisting of bromine, fluorine, and iodine instead of 1-stearyl-3-carbamidopyridinium chloride, but both showed similar properties. Ta. Example 2 A cleansing lotion having the following composition was prepared. The preparation procedure is exactly the same as in Example 1. Group 1: 1-cetyl-3-carbamidopyridinium chloride 0.8% Cetostearyl alcohol 1.2 Vaseline 5.0 Liquid paraffin 11.0 Isopropyl palmitate 2.0 Fragrance 0.1 Preservative 0.2 Group 2: 1,3-Butylene glycol 5.0 Purified water 74.7 The cleansing lotion was stable for more than 3 months in an oven test at 45°C, was non-irritating, and had a very good feel when used. Example 3 A skin cream having the following composition was prepared. Group 1: 1-stearyl-3-carbamidopyridinium chloride 1.0% Cetostearyl alcohol 5.0 Squalane 10.0 Stearic acid 8.0 Beeswax 2.0 Olive oil 3.0 Flavor 0.1 Preservatives 0.2 Group 2: 1,3-Butylene glycol 8.0 Glycerin 4.0 Purified water 58.7 The preparation procedure was exactly the same as in Example 1, and the obtained skin cream was stable for more than 3 months in an oven test at 45°C, was non-irritating, and had a very good feel when used. Example 4 A cleansing cream having the composition shown below was prepared. Group 1: 1-benzyl-3-stearylcarbamide pyridinium chloride 2.0% Cetostearyl alcohol 3.0 Liquid paraffin 35.0 Paraffin wax 2.0 Isopropyl palmitate 10.0 Group 2: Maltitol 3.0 Purified water 45.0 The preparation procedure is exactly the same as Example 1 The resulting cleansing cream was stable for more than 3 months in an oven test at 45°C, was non-irritating, and had a very good feeling of use. Example 5 A lotion having the following composition was prepared. 1st group: 1-lauryl-3-carbamidopyridinium chloride 0.60% fragrance 0.20 oleyl alcohol 0.04 1,3-butylene glycol 1.00 glycerin 1.00 2nd group: citric acid 0.07 purified water 97.06 That is, the solution consisting of the first group Two groups of aqueous solutions were added and sufficiently stirred until uniformly and transparently dissolved. The resulting transparent lotion has a mild effect on the skin, and because it solubilizes fragrances and oils without using ethyl alcohol, which is included in regular lotions, it feels very good on the skin. It was good and warm. In addition, when the bacteriostatic effect was investigated for Examples 1 to 5, a remarkable effect was observed at least for miscellaneous bacteria. Example 6 A human patch test was carried out using the following inspection method and determination method. (1) Application material Finn chamber (2) Application site: Inner upper arm (3) Application time: 24 hours (4) Judgment: 1 hour and 7 hours after removal (5) Judgment criteria: Japanese standards (-) No reaction (±) Slight erythema (+) Obvious erythema (〓) Erythema + edema or papules (〓) Erythema + edema + papules or vesicles (〓) Erythema + edema + papules + vesicles (6) Sample 0.5w/w of horn sample as active ingredient % aqueous solution was used. (a) Distilled water (blank) (b) 1-stearyl-3-carbamidopyridium chloride (inventive product) (c) Cetylpyridinium chloride (control product) (d) 1-dodecyl-3-oxypyridinium bromide (control product) (e) Cetyltrimethylammonium chloride (control product) The obtained results are shown in Table 1.
The primary irritation of -stearyl-3-carbamidopyridinium chloride (product of the present invention) is comparable to that of distilled water, and is considered to be much less irritating than other cationic surfactants (products compatible with cosmetic bases).
【表】
実施例 7
1−ステアリル−3−カルバミドピリジニウム
クロライド(本発明品)の抗菌性テストをつぎに
示す要領で実施した。
供試品
(a) 1−ステアリル−3−カルバミドピリジニウ
ムクロライド(本発明品)
(b) セチルピリジニウムクロライド(対照品)
供試菌
Staphylococus aureus(黄色ブドウ状球菌)
試験方法
所定の濃度に供試品を0.5%Tween80水溶液に
溶して、30℃に保持する。各濃度の供試品を菌液
で接種し、30分、1時間後に一白金耳取り、
SCDブロス(大五栄養社製)に接種して、発育
を観察する。
培養条件
30℃、36時間
得られた結果を第2表にまとめた。この表から
1−ステアリル−3−カルバミドピリジニウムク
ロライドの黄色ブドウ状球菌の抗菌性を示す濃度
は0.1%以上であり、セチルピリジニウムクロラ
イドの抗菌性を示す濃度は0.01%以上であつた。
また、供試菌としてStaphylococous aureusを用
いたのは、「化粧品原料基準第二版注解I」第193
頁に記載されているようにアルキルピリジニウム
塩の抗菌性を試験するのに最も代表的な菌である
と考えたからである。なお、本発明品の抗菌性
は、セチルピリジニウムクロライドの抗菌性から
考えられると、この効果は低く、静菌性を有する
程度と考えられる。[Table] Example 7 An antibacterial test of 1-stearyl-3-carbamidopyridinium chloride (product of the present invention) was conducted in the following manner. Sample (a) 1-stearyl-3-carbamidopyridinium chloride (product of the present invention) (b) Cetylpyridinium chloride (control product) Test bacteria Staphylococcus aureus Test method Sample at a specified concentration Dissolve in 0.5% Tween 80 aqueous solution and keep at 30℃. Inoculate the test sample of each concentration with bacterial solution, take a loop of platinum after 30 minutes and 1 hour,
Inoculate SCD broth (manufactured by Daigo Nutrition Co., Ltd.) and observe growth. Culture conditions: 30°C, 36 hours The results obtained are summarized in Table 2. From this table, the concentration of 1-stearyl-3-carbamidopyridinium chloride showing antibacterial activity against Staphylococcus aureus was 0.1% or more, and the concentration of cetylpyridinium chloride showing antibacterial activity was 0.01% or more.
In addition, Staphylococous aureus was used as the test bacterium according to "Cosmetic Ingredients Standards 2nd Edition Commentary I" 193.
This is because we thought that this is the most representative bacterium for testing the antibacterial properties of alkylpyridinium salts, as described on page 12. Note that, considering the antibacterial properties of the product of the present invention, this effect is low considering the antibacterial properties of cetylpyridinium chloride, and it is considered that the product has bacteriostatic properties.
【表】
以上の実施例6および7の結果から明らかなよ
うにこの発明の皮膚外用剤は従来たとえば特開昭
56−139462号公報、同−139463号公報などに開示
されている界面活性剤に比べて温和な静菌作用を
有する安全性の高い界面活性剤であるということ
ができる。[Table] As is clear from the results of Examples 6 and 7 above, the skin external preparation of the present invention has been developed in the past, for example, by
It can be said that it is a highly safe surfactant that has mild bacteriostatic action compared to the surfactants disclosed in Japanese Patent Nos. 56-139462 and 139463.
Claims (1)
ニコチン酸誘導体を含有することを特徴とする皮
膚外用剤。 記 (式中、R1は炭素数8〜30の直鎖もしくは分枝ア
ルキル基、R2は炭素数1〜30の直鎖もしくは分
枝アルキル基およびフエニル基、Xはハロゲン基
を表わす。)[Scope of Claims] 1. A skin external preparation characterized by containing a nicotinic acid derivative represented by the following general formula [A] or [B]. Record (In the formula, R 1 represents a straight chain or branched alkyl group having 8 to 30 carbon atoms, R 2 represents a straight chain or branched alkyl group having 1 to 30 carbon atoms and a phenyl group, and X represents a halogen group.)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59052496A JPS60197611A (en) | 1984-03-19 | 1984-03-19 | External agent for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59052496A JPS60197611A (en) | 1984-03-19 | 1984-03-19 | External agent for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60197611A JPS60197611A (en) | 1985-10-07 |
JPS6245201B2 true JPS6245201B2 (en) | 1987-09-25 |
Family
ID=12916324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59052496A Granted JPS60197611A (en) | 1984-03-19 | 1984-03-19 | External agent for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60197611A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3751759D1 (en) * | 1986-08-07 | 1996-05-02 | Puetter Medice Chem Pharm | N-alkylated quaternary nitrogen-containing heterocycles, processes for their preparation and their use in medicinal products |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56139462A (en) * | 1980-04-02 | 1981-10-30 | Agency Of Ind Science & Technol | Oxypyridine derivative and surface active agent comprising it |
JPS56139463A (en) * | 1980-04-02 | 1981-10-30 | Agency Of Ind Science & Technol | Aminopyridine derivative and surface active agent comprising it |
-
1984
- 1984-03-19 JP JP59052496A patent/JPS60197611A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56139462A (en) * | 1980-04-02 | 1981-10-30 | Agency Of Ind Science & Technol | Oxypyridine derivative and surface active agent comprising it |
JPS56139463A (en) * | 1980-04-02 | 1981-10-30 | Agency Of Ind Science & Technol | Aminopyridine derivative and surface active agent comprising it |
Also Published As
Publication number | Publication date |
---|---|
JPS60197611A (en) | 1985-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3740575C2 (en) | Lipophilic quaternary ammonium salicylates and pharmaceutical and cosmetic compositions containing them | |
US5019567A (en) | Benzoyl peroxide--quaternary ammonium lipophilic salicylate based pharmaceutical and cosmetic compositions and their use especially in treatment of acne | |
JPS6391313A (en) | Medicine and antiacne cosmetic composition | |
JPH0427962B2 (en) | ||
JPS6160801B2 (en) | ||
JPS60142920A (en) | Anti-acne agent | |
EP0335115A2 (en) | Pharmaceutical and cosmetical compositions on the base of benzoyl peroxide and quaternary ammonium salts | |
JP2001010925A (en) | Emulsified composition | |
JP2907640B2 (en) | Skin external preparation for acne vulgaris | |
US4612193A (en) | Sty ointment and method of using the same | |
JPH05301811A (en) | Beautifying and whitening cosmetic | |
DE60013947T2 (en) | (Poly) thia-alkyne compounds and their derivatives, compositions containing them and their use | |
GB2181051A (en) | Anti-acne compositions | |
FR2613719A1 (en) | AROMATIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIMICROBIALS | |
JPS6245201B2 (en) | ||
JP2696523B2 (en) | Anti-dandruff agent and hair cosmetic | |
JPS6256411A (en) | Beautifying agent | |
WO1990015588A1 (en) | Hair growth stimulant | |
US20010051139A1 (en) | Treating skin afflictions/conditions with 2-amino-4-alkylaminopyrimidine 3-oxide compounds | |
JP4349809B2 (en) | Collagen production promoter | |
US2617753A (en) | Fungistatic preparations | |
DE60018647T2 (en) | Use of 4,6-dimethoxyindole-2-carboxylic acid or its derivatives for the treatment of seborrhoea | |
JPH07149622A (en) | Beautifying and whitening preparation | |
JPH0543465A (en) | Corticosteroid-containing lotion | |
JPS6144814A (en) | Dermal drug for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |